home / stock / wizp / wizp news

WIZP News and Press, Wize Pharma Inc From 01/21/20

Stock Information
Company Name: Wize Pharma Inc
Stock Symbol: WIZP
Market: OTC
Menu
WIZP WIZP Quote WIZP Short WIZP News WIZP Articles WIZP Message Board
Get WIZP Alerts

News, Short Squeeze, Breakout and More Instantly...
WIZP - Wize Pharma completes enrollment in post-marketing study of EyeCon eye drop

Wize Pharma ( OTCQB:WIZP ) has completed enrollment in a Phase 4 clinical trial evaluating eye drop LO2A, branded as EyeCon in Israel, for the symptomatic treatment of dry eye syndrome (DES) in patients with an autoimmune disorder called Sjögren's syndrome (the immune system attacks g...
WIZP - Wize Pharma Completes Patient Enrollment In Phase IV Study Of LO2A for the Treatment of Dry Eye Syndrome in Patients With Sjögren's Syndrome

HOD HASHARON, Israel , Jan. 21, 2020 /PRNewswire/ -- Wize Pharma , Inc. (OTCQB: WIZP) ("Wize"),  a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced it has completed enrolment in its Phase IV clinical trial of its eye drop for...

WIZP - Wize Pharma Executes Agreements for Strategic Transaction With Bonus BioGroup

HOD HASHARON, Israel , Jan. 16, 2020 /PRNewswire/ --  Wize Pharma , Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that it has entered into a strategic transaction with Bonus BioGroup Ltd. (TASE: BONS.T...

WIZP - Wize Pharma Lenders Convert $760,000 of Loans Into Equity

HOD HASHARON, Israel , Dec. 3, 2019 /PRNewswire/ --  Wize Pharma , Inc. (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced it amended the terms of certain convertible loans which had total outstanding amounts of ...
WIZP - Wize Pharma Enters Exclusive License Agreement for Ophthalmic Non-viral Gene Therapy Technology

HOD HASHARON, Israel , Sept. 9, 2019 /PRNewswire/ -- Wize Pharma , Inc. (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced it has entered into an Exclusive License Agreement with U.S.-based Copernicus Therapeutics...

WIZP - Wize Pharma Retains Life Science Advisory Firm Lighthouse BioPartners to Support Potential Pharma Partnership Deals for its Lead Asset LO2A

HOD HASHARON, Israel , July 8, 2019 /PRNewswire/ -- Wize Pharma , Inc. (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, announced today that it has retained Lighthouse BioPartners, LLC a US-based firm specialized in partnering and...

WIZP - Wize Pharma Completes Milestone for Joint Venture With Cannabics Pharmaceuticals; Companies to Develop Cannabinoid Ophthalmic Treatments

HOD HASHARON, Israel , June 28, 2019 /PRNewswire/ -- Wize Pharma , Inc. (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, announced today that the Company and Cannabics Pharmaceuticals (OTCQB: CNBX) have together created and adop...
WIZP - Wize Pharma Interview to Air on Bloomberg International on the RedChip Money Report June 16, 2019

LOS ANGELES , June 14, 2019 /PRNewswire/ -- Wize Pharma, Inc. (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced an interview with its CEO, Noam Danenberg , will air on The RedChip Money Report television prog...

WIZP - Wize Pharma Issues Letter to Shareholders

HOD HASHARON, Israel , May 21, 2019 /PRNewswire/ -- Wize Pharma , Inc. (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today issued a Letter to Shareholder. Dear Fellow Shareholders, We are very pleased to report on o...

WIZP - Wize Pharma to Present at ThinkEquity Conference on May 2, 2019 in New York City

HOD HASHARON, Israel , April 30, 2019 /PRNewswire/ --  Wize Pharma , Inc. (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced it will present at the ThinkEquity Conference on May 2, 2019 at 2:30 pm ET at the...
Previous 10 Next 10